secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001437749-24-017504
Event type: litigation
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca
--------------------------------------------------------------------------------

- Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.
- Puma was dismissed as plaintiff but retains contractual right to recover damages under Pfizer license.
- Bench trial on equitable defenses (unclean hands, patent misuse) set for June 17-18, 20, 2024.
- Further proceedings will determine ongoing royalty rate through patent term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924017504/0001437749-24-017504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924017504/pbyi20240517_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer